These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 19187349)
1. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. Schaefer W BJU Int; 2009 Feb; 103(4):554-5. PubMed ID: 19187349 [No Abstract] [Full Text] [Related]
2. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J; BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175 [TBL] [Abstract][Full Text] [Related]
3. [A placebo-controlled, double-blind, randomized trial of single daily dose of anti-muscarinic drug solifenacin succinate in patients with overactive bladder]. Cardozo L; Lisec M; Milard R; Van Vierssen Trip O; Kuzmin I; Drogendijk TE; Huang AM Akush Ginekol (Sofiia); 2007; 46(5):55-7. PubMed ID: 17974184 [No Abstract] [Full Text] [Related]
4. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Karram MM; Toglia MR; Serels SR; Andoh M; Fakhoury A; Forero-Schwanhaeuser S Urology; 2009 Jan; 73(1):14-8. PubMed ID: 18995887 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Wagg A; Wyndaele JJ; Sieber P Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617 [TBL] [Abstract][Full Text] [Related]
6. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Toglia MR; Serels SR; Laramée C; Karram MM; Nandy IM; Andoh M; Seifeldin R; Forero-Schwanhaeuser S Postgrad Med; 2009 Sep; 121(5):151-8. PubMed ID: 19820284 [TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M; BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143 [TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W J Urol; 2009 Dec; 182(6):2825-30. PubMed ID: 19837435 [TBL] [Abstract][Full Text] [Related]
10. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study. Yamaguchi O; Kakizaki H; Homma Y; Takeda M; Nishizawa O; Gotoh M; Yokoyama O; Seki N; Yoshida M; Urology; 2011 Jul; 78(1):126-33. PubMed ID: 21601248 [TBL] [Abstract][Full Text] [Related]
11. Solifenacin. Kreder KJ Urol Clin North Am; 2006 Nov; 33(4):483-90, ix. PubMed ID: 17011384 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. Yokoyama O; Yamaguchi O; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M; Yamada S J Urol; 2011 Jul; 186(1):170-4. PubMed ID: 21575976 [TBL] [Abstract][Full Text] [Related]
14. Solifenacin: scientific evidence in the treatment of overactive bladder. Santos JC; Telo ER Arch Esp Urol; 2010 Apr; 63(3):197-213. PubMed ID: 20431184 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. Millard RJ; Halaska M Curr Med Res Opin; 2006 Jan; 22(1):41-8. PubMed ID: 16393429 [TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency. Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W J Urol; 2013 Jan; 189(1 Suppl):S129-34. PubMed ID: 23234618 [TBL] [Abstract][Full Text] [Related]
17. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. Kelleher CJ; Cardozo L; Chapple CR; Haab F; Ridder AM BJU Int; 2005 Jan; 95(1):81-5. PubMed ID: 15638900 [TBL] [Abstract][Full Text] [Related]
18. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Chapple CR; Cardozo L; Steers WD; Govier FE Int J Clin Pract; 2006 Aug; 60(8):959-66. PubMed ID: 16893438 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Gollar KM; Young DG; Bailen J; He W; Forero-Schwanhaeuser S Urol Nurs; 2012; 32(1):38-46, 50. PubMed ID: 22474864 [TBL] [Abstract][Full Text] [Related]
20. Solifenacin succinate for the treatment of symptoms of overactive bladder. Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]